Infection 2005, 33:340–344 PubMedCrossRef 3 Meyns E, Vermeersch

Infection 2005, 33:340–344.PubMedCrossRef 3. Meyns E, Vermeersch N, Ilsen B, Hoste W, Delooz H, Hubloue I: Spontaneous intrahepatic gas gangrene and fatal septic shock. Acta Chir Belg 2009, 109:400–404.PubMed 4. Rood JI: Virulence genes of Clostridium perfringens . Annu Rev Microbiol 1998, 52:333–360.PubMedCrossRef 5. Sparks SG, Carman RJ, Sarker MR, McClane BA: Genotyping of enterotoxigenic Clostridium selleck screening library perfringens fecal isolates associated with antibiotic-associated diarrhea and food poisoning in North America. J Clin Microbiol 2001, 39:883–888.PubMedCrossRef 6. Petit L, Gibert M, Popoff MR: Clostridium perfringens: toxinotype and genotype. Trends Microbiol

1997, 179:104–110. 7. Titball RW, Hunter check details SE, Martin KL, Morris BC, Shuttleworth AD, Rubidge T: et al: Molecular cloning and nucleotide sequence of the alpha-toxin (phospholipase C) of Clostridium perfringens . Infect Immun 1989, 57:367–376.PubMed 8. Lazarescu C, Kimmoun A, Blatt A, Bastien C,

Levy B: et al: Clostridium perfringens gangrenous cystitis with septic shock and bone marrow necrosis. Intensive Care Med 2012, 38:1906–1907.PubMedCrossRef 9. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD: Eradication of pathogenic bacteria and restoration of normal pouch flora: comparison of metronidazole and ciprofloxacin in the treatment of pouchitis. Dis Colon Rectum 2004, 47:1519–1525.PubMedCrossRef 10. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P: Antibiotic AZD0156 combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999, 13:713–718.PubMedCrossRef 11. Leal J, Gregson DB, Ross T, Church DL, Laupland KB: Epidemiology of Clostridium species bacteremia in Calgary, Canada, 2000–2006. J Infect 2008, 5:198–203.CrossRef 12. Leukotriene-A4 hydrolase Wexler HM, Molitoris E, Finegold SM: In vitro activities of three of the newer quinolones against anaerobic bacteria. Antimicrob Agents Chemother 1992, 36:239–234.PubMedCrossRef 13.

Ferrero L, Cameron B, Crouzet J: Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus . Antimicrob Agents Chemother 1995, 39:1554–1558.PubMedCrossRef 14. Tamayo M, Santiso R, Gosalvez J, Bou G, Fernandez JL: Rapid assessment of the effect of ciprofloxacin on chromosomal DNA from Escherichia coli using an in situ DNA fragmentation assay. BMC Microbiol 2009, 9:69.PubMedCrossRef 15. Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN: Complete and SOS-mediated response of Staphylococcus aureus to the antibiotic ciprofloxacin. J Bacteriol 2007, 189:531–539.PubMedCrossRef 16. Dorr T, Lewis K, Vulic M: SOS response induces persistence to fluoroquinolones in Escherichia coli . PLoS Genet 2009, 5:e1000760.PubMedCrossRef 17. Dorr T, Vulic M, Lewis K: Ciprofloxacin causes persister formation by inducing the TisB toxin in Escherichia col i .

Comments are closed.